A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug ...

Bristol Myers Squibb (BMY) and GSK PLC (GSK) are among the largest global biopharma companies with broad and diverse ...

D ynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

The cast of 9-1-1 is still getting used to Peter Krause’s absence on set, but Angela Bassett doesn’t think the aftermath of ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Hadley Property Group has submitted plans to transform GSK House, biopharma company GSK's former headquarters in west London, ...

Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a ...

With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections (uUTIs ...